You might also experience headaches, dizziness, or water retention
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
AOD 9604 peptide appeared to exhibit action similar to hGH wherein both may be capable of increasing repressed levels of lipolytic receptors in obese mice as compared to the lean mice
Injury Recovery & Musculoskeletal Repair Many patients especially those with chronic tendon injuries, ligament tears, muscle strains, or post-surgical recovery issues seek peptide therapy after conventional treatments have provided limited relief